TG Therapeutics Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
33.86
-0.99
(-2.84%)
Volume:
3,626,211
52 week range:
15.16 - 46.48
Market Cap:
5.318B
Company Description:
TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.